-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Raises Price Target to $17

Benzinga·04/06/2026 15:16:41
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $14 to $17.